AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients – STAT
STAT |
AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients
STAT AstraZeneca still trails cancer immunotherapy leaders Merck and Bristol-Myers Squibb, but staking a claim in lung cancer marks progress. In the phase 3 clinical trial AstraZeneca calls PACIFIC, the checkpoint inhibitor Imfinzi cut the risk of tumor … AstraZeneca rebuilds cancer drug hopes with new lung data |
